HeartBeam's balance sheet expanded substantially with cash growing by 84% while total liabilities roughly doubled, reflecting significant financing activity during the period.
The company appears to have completed a meaningful capital raise, substantially improving its cash position to $4.4M, which is critical for this early-stage medical technology company. However, the doubling of liabilities warrants monitoring as it could indicate increased operational burn or new debt obligations that may pressure future cash flows.
HeartBeam's financial profile shows clear signs of capital infusion with cash and equivalents growing by 84% to $4.4M and total assets expanding by 78% to $5.8M. The doubling of total liabilities to $3.2M alongside increased stockholders' equity suggests a combination of equity financing and potentially new operational obligations. R&D expenses increased modestly by 22% to $13.4M, indicating continued investment in the company's cardiac monitoring technology development.
Liabilities grew 99.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Cash position surged 84.3% — strong cash generation or capital raise providing significant financial cushion.
Asset base grew 78.4% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 69.1% — improving short-term liquidity or inventory/receivables build.
Equity base grew 57.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
R&D investment increased 21.7% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →